# Maternal-Fetal Medicine Consultation

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Mumtaz Mahal (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-RE006-SYN
- Date: 2026-02-03
- Fictional facility: St. Posthumous Health Center
- Fictional author: Adaeze Montgomery-Rahimi, MD
- Calendar frame: modern shifted

- Requested by: Farzana Qureshi-Lindholm, MD

## Reason for consultation

Fourteenth pregnancy at 37, at 13 weeks 2 days by today's scan, conceived about five and a half months after her last birth, with iron deficiency anemia. Please advise on surveillance, anemia treatment, placental assessment, the timing and place of birth, and planning to prevent postpartum hemorrhage. **S**

## History

Mumtaz Mahal is seen at the request of Dr. Qureshi-Lindholm at 17 weeks 2 days. She has had thirteen vaginal births, all by her account at or near term, with labors that were often short, and no cesarean, uterine surgery, or blood transfusion; she does not know of heavy bleeding after any birth. One baby died soon after birth, and five other children died in infancy or early childhood. This pregnancy began about five and a half months after her last birth. She has taken about half of her oral iron doses because of nausea and constipation and remains tired. She has no bleeding, pain, or urinary symptoms and has felt the first movements. She travels often with her family and expects to travel again in the spring. She wants clear plans and prefers women clinicians. **S**

## Examination

| System | Finding |
|---|---|
| General | Well; pale conjunctivae |
| Abdomen | Uterus consistent with 17 weeks; non-tender; no scars |
| Fetal | Fetal heart 152 per minute |

BP 106/64 mmHg; pulse 86 bpm; respirations 14/min; temperature 36.6 °C; oxygen saturation 99% on room air; weight 59.8 kg; BMI 24.3 kg/m². All vital signs are synthetic.

## Data reviewed

The dating and nuchal translucency scan; cell-free DNA (low risk); blood group O RhD positive with a negative antibody screen; rubella immune; hepatitis B, HIV, syphilis, and hepatitis C negative; urine culture no growth; hemoglobin electrophoresis normal; hemoglobin 10.1 g/dL with ferritin 9 ng/mL at intake and 10.3 g/dL with ferritin 12 ng/mL today; hemoglobin A1c 5.4 percent; today's vital signs (blood pressure 106/64 mmHg, weight 59.8 kg). Hemoglobin: 10.3 g/dL (low); Ferritin: 12 ng/mL (low). All results are synthetic.

## Assessment

1. **Fourteenth pregnancy at 37** (O09.529). A singleton pregnancy at an advanced maternal age with a low-risk aneuploidy screen. Age 35 or older raises the risks of preeclampsia, gestational diabetes, fetal growth restriction, and stillbirth; aspirin is correctly started. **S**
2. **Grand multiparity** (O09.40). Thirteen previous births raise the risks of uterine atony and postpartum hemorrhage, malpresentation, and fast labor. Without a uterine scar, the risk of placenta accreta spectrum is low unless the placenta lies over the cervix. **S**
3. **Short interpregnancy interval** (O09.899). An interval under six months from birth to conception is linked to anemia, preterm birth, and a small baby. **S**
4. **Iron deficiency anemia in pregnancy** (O99.019). Iron deficiency anemia that has not responded to oral iron, which she cannot tolerate; thalassemia trait excluded. Anemia at delivery would leave her little reserve if she bleeds. **S**

## Recommendations

1. Intravenous iron now that she is in the second trimester: ferric carboxymaltose 750 mg today and again in four weeks, with hemoglobin and ferritin before each dose and at 24 to 28 weeks; aim for a hemoglobin of at least 11 g/dL before delivery.
2. Detailed anatomy scan at 20 to 22 weeks with placental location; if the placenta is low-lying or over the cervix, repeat at 32 weeks and assess for accreta; otherwise no MRI is needed.
3. Continue aspirin 81 mg nightly until delivery; blood pressure and urine protein at every visit; glucose challenge at 24 to 28 weeks; visits every two weeks from 28 weeks and weekly from 36 weeks; a growth scan at 32 to 34 weeks; weekly fetal heart rate monitoring from 36 weeks can be offered.
4. Birth in a hospital with a blood bank, 24-hour anesthesia, and an operating theatre; offer induction at 39 weeks, which also avoids an unplanned birth away from the hospital.
5. Postpartum hemorrhage plan, written by 36 weeks: risk assessment on admission, type and screen, two large-bore lines, oxytocin 10 units at birth with controlled cord traction, quantitative blood loss, and, if hemorrhage occurs, tranexamic acid 1 g intravenously within 3 hours of birth with a second dose after 30 minutes if bleeding continues, alongside uterotonics, uterine massage, and the hemorrhage protocol; anesthesia consultation at 36 weeks.
6. Travel is reasonable in the second trimester and early third trimester if she stays well: carry her records, keep her prenatal visits where she stays, walk and drink often on long journeys, and stay near the delivery hospital from 36 weeks.
7. Discuss postpartum contraception and the interval before any future pregnancy in the third trimester, in her own terms; advise waiting at least 18 months, ideally 24, after this birth.

## Strengths and supports

- Supports: a large household, her eldest daughter, and a close woman friend who travels with her **S**

## Communication

Discussed with Dr. Qureshi-Lindholm the same day; Mumtaz Mahal agrees with the plan, and the first iron infusion is given today. **S**

## Follow-up

Primary obstetric care continues with Dr. Qureshi-Lindholm. Maternal-fetal medicine will review the anatomy scan and see her again if any problem arises, and in any case before the birth. **S**

## Guideline basis

- Pregnancy at Age 35 Years or Older: ACOG Obstetric Care Consensus No. 11 (2022), American College of Obstetricians and Gynecologists and Society for Maternal-Fetal Medicine (Obstetrics & Gynecology)
- Practice Bulletin No. 183: Postpartum Hemorrhage (2017), American College of Obstetricians and Gynecologists (Obstetrics & Gynecology)
- WHO recommendations for the prevention and treatment of postpartum haemorrhage (2012), World Health Organization
- WHO recommendation on tranexamic acid for the treatment of postpartum haemorrhage (2017), World Health Organization
- Effect of early tranexamic acid administration on mortality, hysterectomy, and other morbidities in women with post-partum haemorrhage (WOMAN): an international, randomised, double-blind, placebo-controlled trial (2017), WOMAN Trial Collaborators (The Lancet)
- Anemia in Pregnancy: ACOG Practice Bulletin, Number 233 (2021), American College of Obstetricians and Gynecologists (Obstetrics & Gynecology)
- Aspirin Use to Prevent Preeclampsia and Related Morbidity and Mortality: Preventive Medication (2021), U.S. Preventive Services Task Force
- ACOG Practice Bulletin No. 190: Gestational Diabetes Mellitus (2018), American College of Obstetricians and Gynecologists (Obstetrics & Gynecology)
- Obstetric Care Consensus No. 7: Placenta Accreta Spectrum (2018), American College of Obstetricians and Gynecologists and Society for Maternal-Fetal Medicine (Obstetrics & Gynecology)
- ACOG Committee Opinion No. 746: Air Travel During Pregnancy (2018), American College of Obstetricians and Gynecologists (Obstetrics & Gynecology)
- Obstetric Care Consensus No. 8: Interpregnancy Care (2019), American College of Obstetricians and Gynecologists and Society for Maternal-Fetal Medicine (Obstetrics & Gynecology)
